secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001193125-22-276477
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Therapeutics Q3 net loss $16.1M; cash $128.3M funds into Q2 2024
------------------------------------------------------------------------

- Cash, equivalents and marketable securities $128.3M at Sept 30, 2022, down from $176.9M at Dec 31, 2021.
- Net loss of $16.1M for Q3 2022 vs $17.4M in Q3 2021; R&D expense $11.2M, G&A $6.1M.
- MGTA-117 Phase 1/2 trial in AML/MDS progressing; no related SAEs or DLTs; Cohort 3 enrollment completed.
- CD45-ADC toxicology study done; IND-enabling ongoing; program update expected Dec 2022.
- MGTA-145 sickle cell trial enrolling; initial data anticipated Dec 2022, comprehensive data H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522276477/0001193125-22-276477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522276477/d349418d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-276477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer